Cancer Biomarkers in Body Fluids : Biomarkers in Circulation

This book examines in depth the evidence, clinical applications and potential cancer signatures in the circulation and discusses alterations in circulating cell-free nucleic acids, and circulating tumor DNA, as well as the epigenome, genome, transcriptome (coding and noncoding), proteome (both tradi...

Full description

Saved in:
Bibliographic Details
Main Author: Dakubo, Gabriel D., (Author)
Format: eBook
Language: English
Published: Cham, Switzerland : Springer, [2017]
Subjects:
Cancer > Molecular diagnosis.
Cancer > Genetic aspects.
Biochemical markers.
elektronické knihy
electronic books
ISBN: 9783319483603
9783319483597
Physical Description: 1 online resource (xix, 519 pages) : illustrations (some color)

Cover

Table of contents

LEADER 05874cam a2200469Mi 4500
001 97122
003 CZ-ZlUTB
005 20240914110346.0
006 m o d
007 cr |n|||||||||
008 161202s2017 sz a ob 001 0 eng d
040 |a YDX  |b eng  |e rda  |e pn  |c YDX  |d OCLCO  |d N$T  |d GW5XE  |d IDEBK  |d OCLCA  |d OCLCF  |d N$T  |d AZU  |d UAB  |d OCLCO  |d COO  |d N$T  |d OCLCO  |d UPM  |d IOG  |d OCLCO  |d VT2  |d MERER  |d ESU  |d Z5A  |d OCLCO  |d JBG  |d IAD  |d OCLCO  |d ICW  |d OCLCO  |d ICN  |d OCLCQ  |d OCLCO  |d OTZ  |d OCLCQ  |d OCLCO  |d JG0  |d OCLCO  |d U3W  |d OCLCO  |d OCLCA  |d CAUOI  |d AU@  |d OCLCO  |d OCLCQ  |d WYU  |d OCLCA  |d UKMGB  |d OCLCO  |d OCLCQ  |d OCLCO  |d ERF  |d OCLCA 
020 |a 9783319483603  |q (electronic bk.) 
020 |z 9783319483597 
024 7 |a 10.1007/978-3-319-48360-3  |2 doi 
035 |a (OCoLC)966563464  |z (OCoLC)964585818  |z (OCoLC)964931388  |z (OCoLC)974651424  |z (OCoLC)981099330  |z (OCoLC)1005810185  |z (OCoLC)1048144728  |z (OCoLC)1058293295  |z (OCoLC)1066471252  |z (OCoLC)1066492569  |z (OCoLC)1097094609  |z (OCoLC)1112537539 
100 1 |a Dakubo, Gabriel D.,  |e author. 
245 1 0 |a Cancer Biomarkers in Body Fluids :  |b Biomarkers in Circulation /  |c Gabriel D. Dakubo. 
264 1 |a Cham, Switzerland :  |b Springer,  |c [2017] 
300 |a 1 online resource (xix, 519 pages) :  |b illustrations (some color) 
336 |a text  |b txt  |2 rdacontent 
337 |a počítač  |b c  |2 rdamedia 
338 |a online zdroj  |b cr  |2 rdacarrier 
505 0 |a Preface; Contents; About the Author; Chapter 1: Melanoma Biomarkers in Circulation; Key Topics; 1.1 Introduction; 1.2 Screening Recommendations for Melanoma; 1.3 Molecular Pathology of Melanoma; 1.3.1 BRAF Mutations in Melanoma; 1.3.2 RAS Mutations in Melanoma; 1.3.3 Alterations in Cell Cycle Control Genes in Melanoma; 1.3.4 TP53 Mutations in Melanoma; 1.3.5 KIT Mutations in Melanoma; 1.3.6 MITF Mutations in Melanoma; 1.3.7 PI3K Pathway Alterations in Melanoma; 1.3.8 Molecular Subtypes of Melanoma; 1.3.9 Molecular Progression Model of Melanoma; 1.4 Circulating Melanoma Biomarkers. 
505 8 |a 1.4.1 Circulating Melanoma Cell-Free Nucleic Acid Biomarkers1.4.2 Circulating Melanoma Epigenetic Biomarkers; 1.4.3 Circulating Melanoma Genetic Biomarkers; 1.4.3.1 Mutations as Circulating Melanoma Biomarkers; 1.4.3.2 Circulating MSA as Melanoma Biomarkers; 1.4.4 Circulating Melanoma Coding RNA Biomarkers; 1.4.5 Circulating Melanoma Noncoding RNA Biomarkers; 1.4.6 Circulating Melanoma Protein Biomarkers; 1.4.6.1 Serum S100beta as Melanoma Biomarker; 1.4.6.2 Serum LDH as Melanoma Biomarker; 1.4.6.3 Serum MIA as Melanoma Biomarker; 1.4.6.4 Serum VEGF as Melanoma Biomarker. 
505 8 |a 1.4.6.5 Serum Levodopa to l-Tyrosine Ratio as Melanoma Biomarker1.4.6.6 Serum Cysteinyldopa as Melanoma Biomarker; 1.4.6.7 Serum Autoantibodies as Melanoma Biomarkers; 1.4.6.8 Circulating Melanoma Proteomic Biomarkers; 1.4.7 Circulating Melanoma Cells; 1.4.7.1 Molecular Approaches to CMCs; 1.4.7.2 CMCs in Advanced Stage III and IV Melanoma; 1.4.7.3 CMCs in Uveal Melanoma; 1.4.8 Melanoma Extracellular Vesicles; 1.4.9 Summary; References; Chapter 2: Head and Neck Cancer Biomarkers in Circulation; Key Topics; 2.1 Introduction; 2.2 Screening Recommendations for HNC. 
505 8 |a 2.3 The Need for Noninvasive Screening Tests for HNC2.4 Molecular Pathology of HNC; 2.4.1 Molecular Classification of HNC; 2.4.2 Molecular Pathology of HPV-Positive HNC; 2.4.3 Specific Genetic Alterations in HNC; 2.4.3.1 EGFR Alterations in HNC; 2.4.3.2 TGFbeta Pathway Alterations in HNC; 2.4.3.3 PI3K/AKT Pathway Alterations in HNC; 2.4.3.4 TP53 Alterations in HNC; 2.4.3.5 Cell Cycle Gene Alterations in HNC; 2.4.3.6 MET Alterations in HNC; 2.4.3.7 Telomere Alterations in HNC; 2.5 Circulating HNC Biomarkers; 2.5.1 Circulating Cell-Free Nucleic Acids as HNC Biomarkers. 
505 8 |a 2.5.2 Circulating HNC Epigenetic Biomarkers2.5.3 Circulating HNC Noncoding RNA Biomarkers; 2.5.3.1 Oncomirs and Tumor Suppressormirs in HNC; 2.5.3.2 Circulating HNC miRNA Biomarkers; 2.5.4 Circulating HNC Serum Protein Biomarkers; 2.5.5 Circulating HNC Cells; 2.5.5.1 Methodologies for CHNCC Analysis; 2.5.5.2 CHNCCs as Staging Biomarkers; 2.5.5.3 CHNCCs as Prognostic Biomarkers; 2.5.5.4 CHNCCs as Predictive Biomarkers; 2.5.5.5 Induction of CHNCCs by Clinical Interventions; 2.5.6 Circulating HPV-Positive HNC Biomarkers; 2.5.7 HNC Extracellular Vesicles; 2.6 Nasopharyngeal Carcinoma. 
504 |a Includes bibliographical references and index. 
506 |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty 
520 |a This book examines in depth the evidence, clinical applications and potential cancer signatures in the circulation and discusses alterations in circulating cell-free nucleic acids, and circulating tumor DNA, as well as the epigenome, genome, transcriptome (coding and noncoding), proteome (both traditional serum proteins and proteomic profiles) and metabolome. Further, it highlights the clinical applications of circulating tumor cells for each cancer type and addresses the emerging importance of extracellular vesicular contents, including miRNA, oncogenes and drug resistant factors. As such, it offers a valuable reference guide for cancer researchers, oncologists, clinicians, surgeons, medical students, oncology nurses, diagnostic laboratories, and the pharmaceutical industry. 
590 |a SpringerLink  |b Springer Complete eBooks 
650 0 |a Cancer  |x Molecular diagnosis. 
650 0 |a Cancer  |x Genetic aspects. 
650 0 |a Biochemical markers. 
655 7 |a elektronické knihy  |7 fd186907  |2 czenas 
655 9 |a electronic books  |2 eczenas 
776 0 8 |i Print version:  |z 3319483595  |z 9783319483597  |w (OCoLC)959033933 
856 4 0 |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-48360-3  |y Plný text 
992 |c NTK-SpringerBLS 
999 |c 97122  |d 97122 
993 |x NEPOSILAT  |y EIZ 

Similar Items